MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 1.19 and traded as high as GBX 1.26. MaxCyte shares last traded at GBX 1.24, with a volume of 745,949 shares changing hands.
MaxCyte Stock Performance
The company has a market cap of £1.48 million, a PE ratio of -0.03 and a beta of 1.13. The company has a current ratio of 12.39, a quick ratio of 14.38 and a debt-to-equity ratio of 9.70. The business’s 50 day moving average is GBX 1.19 and its two-hundred day moving average is GBX 0.98.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.
Featured Stories
- Five stocks we like better than MaxCyte
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
